Helicobacter pylori infections have long been hard to erase because standard Western regimens (a proton‑pump inhibitor, two antibiotics and bismuth) face rising drug‑resistance, nasty side‑effects and gut‑flora disruption. A 2025 clinical trial by the Gastroenterology team at Peking Union Medical College Hospital shows that pairing modern diagnostics with traditional Chinese medicine can lift the cure rate from about 70% to an impressive 95.2%. The protocol follows three stages: 1. **Pre‑treatment screening** – a C13 breath test and gene‑resistance analysis identify the bacteria’s strengths and the patient’s stomach condition. 2. **Combined therapy (10‑14 days)** – targeted antibiotics are chosen based on resistance results, while classic Chinese formulas (e.g., Banxia Xiexin Tang, berberine) protect the mucosal barrier, break down bacterial bio‑films and rebalance gut flora, allowing lower antibiotic doses and fewer side‑effects. 3. **Post‑treatment conditioning (3 months)** – dietary advice, probiotic support and occasional moxibustion help prevent relapse. A real‑world case of a 42‑year‑old man who failed three prior eradications achieved a negative breath test after the combined regimen and stayed clear at six‑month follow‑up. Experts warn against relying solely on powerful new drugs, ignoring oral H. pylori reservoirs, and indiscriminate probiotic use. This integrated approach signals a shift from “killing the bug” to “re‑balancing the stomach ecosystem.”
Read moreA recent study asked cancer patients whether they would rather wait a year and a half for a new drug that looks promising in early tests, or settle for a treatment whose benefits are measured only by surrogate markers like tumor shrinkage. Most chose the longer wait, showing a strong desire for therapies that feel more like a true cure. The research used a rigorous, patient‑focused design that mirrors real‑world clinical trials and involved top oncologists at every step. Its thorough approach could land it in leading medical journals. Why do many hopeful drugs stumble later? Scientists suspect factors such as oxygen levels in tumors may explain why drugs that shine in the lab often fail in patients. Meanwhile, two high‑profile candidates—Eli Lilly’s CDK4/6 inhibitor Verzenio and Amgen’s bispecific antibody Blincyto—have entered China’s priority‑review pathway, speeding their potential approval. A recent Lancet Oncology review highlighted a decade of progress in Chinese cancer trials, noting both impressive advances and gaps that still need filling. The blockbuster CDK4/6 inhibitors, which block a key cell‑cycle switch, now generate about $4 billion a year worldwide. Another tumor‑agnostic drug has just received clinical clearance in China, expanding treatment options that work across multiple cancer types. Overall, the findings underscore patients’ willingness to gamble on future breakthroughs, while researchers race to turn early promise into real, life‑saving therapies.
Read moreIn a recent interview, Professor Jia Jidong shared his vision for turning the drug‑development landscape from a game of imitation into one of leadership. He argues that the key to becoming a pioneer lies in embracing bold scientific questions, investing in cutting‑edge technologies, and fostering collaborations that go beyond national borders. Jia highlights several emerging trends that are reshaping the industry: a new report from Evaluate’s EP Vantage ranks the ten most valuable biopharma R&D projects, underscoring the financial power of breakthrough therapies; the U.S. Senate’s passage of the FDA Modernization Act 2.0 signals a major shift toward reducing animal testing and speeding up clinical trials; Japan continues to dominate new‑drug approvals, with 406 novel medicines launched between 1996 and 2019, demonstrating the benefits of a focused, domestic pipeline. Jia also points to recent therapeutic advances, such as siponimod for multiple sclerosis patients in China and the surprising revival of Biogen’s Alzheimer’s drug aducanumab, which is now seeking market approval after a halted Phase III trial. Together, these developments illustrate how strategic risk‑taking, regulatory agility, and international cooperation can move a country from merely following trends to setting them. The professor urges Chinese researchers to adopt this mindset, invest in functional cures—like those targeting hepatitis B—and aim for global leadership in the next wave of medical breakthroughs.
Read more